Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant sunitinib biomarker study in clear cell renal cell carcinoma
2007-005648-25Phase 3Active
- Sponsor
- CHU Rennes
- Start
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of sunitinib in clear cell renal cell carcinoma (ccRCC), sponsored by CHU Rennes. Primary endpoints: Cancer-free survival, Predictive value of VHL gene alterations and 1 more. Started Dec 2007; status: active.
02
Drugs
sunitinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2007-005648-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005648-25.